Mohamed Elfil

Dr. Mohamed Elfil

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2020 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MEMohamed Elfil
Mohamed Elfil
SKSerageldin Kamel
Serageldin Kamel
MKMohamed Kandil
Mohamed Kandil
BKBrian B. Koo
Brian B. Koo
SSSara M. Schaefer
Sara M. Schaefer

9 December 2020 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MEMohamed Elfil
Mohamed Elfil
EBEshak I. Bahbah
Eshak I. Bahbah
MAMahmoud M. Attia
Mahmoud M. Attia
MEMohamed Eldokmak
Mohamed Eldokmak
BKBrian B. Koo
Brian B. Koo

1 December 2020 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
ASAhmed Sayed
Ahmed Sayed
EBEshak I. Bahbah
Eshak I. Bahbah
SKSerageldin Kamel
Serageldin Kamel
GBGeorge E. Barreto
George E. Barreto
Ghulam M. AshrafGhulam M. Ashraf
Ghulam M. Ashraf
MEMohamed Elfil
Mohamed Elfil

5 May 2021 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
MAMohammad Aladawi
Mohammad Aladawi
MEMohamed Elfil
Mohamed Elfil
BABaha Abu-Esheh
Baha Abu-Esheh
DJDeaa Abu Jazar
Deaa Abu Jazar
AAAhmad Armouti
Ahmad Armouti
EPEzequiel Piccione
Ezequiel Piccione
Background: In January 2020, the first case of Guillain Barre syndrome (GBS) due to COVID-19 was documented in China. GBS is known to be postinfectious following several types of infections. Although causality can only be proven through large epidemiological studies, we intended to study this association by a thorough review of the literature.Methods: We searched PubMed, EMBASE, and Google scholar and included all papers with English or Spanish full text and original data of patients with GBS and recent COVID infection. Variables of interest were demographics, diagnostic investigations, and the latency between arboviral and neurological symptoms. Further variables were pooled to identify GBS clinical and electrophysiological variants, used treatments, and outcomes. The certainty of GBS diagnosis was verified using Brighton criteria.Results: We identified a total of 109 GBS cases. Ninety-nine cases had confirmed COVID-19 infection with an average age of 56.07 years. The average latency period between the arboviral symptoms and neurologic manifestations for confirmed COVID-19 cases was 12.2 d. The predominant GBS clinical and electromyography variants were the classical sensorimotor GBS and acute demyelinating polyneuropathy respectively. Forty cases required intensive care, 33 cases required mechanical ventilation, and 6 cases were complicated by death.Conclusions: Studies on COVID-19-related GBS commonly reported sensorimotor demyelinating GBS with frequent facial palsy. The time between the onset of infectious and neurological symptoms suggests a postinfectious mechanism. Early diagnosis of GBS in COVID-19 patients is important as it might be associated with a severe disease course requiring intensive care and mechanical ventilation.

1 August 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
MMMahmoud H. Mohammaden
Mahmoud H. Mohammaden
MDMohamed Fahmy Doheim
Mohamed Fahmy Doheim
MEMohamed Elfil
Mohamed Elfil
AAAlhamza R. Al-Bayati
Alhamza R. Al-Bayati
APAgostinho Pinheiro
Agostinho Pinheiro
RNRaul G. Nogueira
Raul G. Nogueira
Background: There is growing evidence to suggest that the direct transfer to angiography suite (DTAS) approach for patients with suspected large vessel occlusion stroke potentially requiring mechanical thrombectomy shortens treatment times and improves outcomes compared with the direct transfer to conventional imaging (DTCI) model. Therefore, we conducted this meta-analysis to compare both approaches to build more concrete evidence to support this innovative treatment concept. Methods: All potentially relevant studies published in 4 electronic databases/search engines (PubMed, Web of Science, Cochrane Library, and Scopus) from inception to November 2021 were reviewed. Eligible studies were included if they enrolled ≥10 patients in both groups, were published in English, and reported baseline and procedural characteristics and outcomes. Relevant data were then extracted and analyzed. Results: Among 4514 searched studies, 7 qualified for the analysis with 1971 patients (DTAS=675, DTCI=1296). Times from door to puncture (mean difference, −30.76 minutes [95% CI, −43.70 to −17.82]; P <0.001) as well as door-to-reperfusion (mean difference=−33.24 minutes [95% CI, −51.82 to −14.66]; P <0.001) were significantly shorter and the rates of functional independence (modified Rankin Scale score, 0–2: risk ratio [RR], 1.25 [95% CI, 1.02–1.53]; P =0.03) at 90 days were higher in the DTAS versus the DTCI approach. There was no difference across the DTAS and DTCI groups in terms of the rates of successful reperfusion (modified Thrombolysis in Cerebral Infarction score 2B–3: RR, 1.03 [95% CI, 0.95–1.12]; P =0.42), near-complete/full reperfusion (modified Thrombolysis in Cerebral Infarction 2C–3: RR, 0.89 [95% CI, 0.74–1.08]; P =0.23), symptomatic intracranial hemorrhage (RR, 0.81 [95% CI, 0.56–1.17]; P =0.26), or fair outcomes (modified Rankin Scale score, 0–3: RR, 1.14 [95% CI, 0.88–1.47]; P =0.32) or mortality (RR, 0.98 [95% CI, 0.67–1.44]; P =0.93) at 90 days. Subgroup analysis showed no significant difference in 90-day functional independence across approaches in transfer patients (RR, 1.20 [95% CI, 0.96–1.51]; P =0.11). Conclusions: Our meta-analysis showed that the DTAS approach seems to be associated with improved time metrics and functional outcomes with comparable safety to the DTCI approach. Ongoing multicenter randomized clinical trials will hopefully provide more definite data about this promising approach.

18 July 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
SJSeyed Behnam Jazayeri
Seyed Behnam Jazayeri
SGSherief Ghozy
Sherief Ghozy
LHLina Hemmeda
Lina Hemmeda
CBCem Bilgin
Cem Bilgin
MEMohamed Elfil
Mohamed Elfil
DKDavid F. Kallmes
David F. Kallmes
BACKGROUND: When treating acute ischemic stroke due to large-vessel occlusion, both mechanical thrombectomy and intravenous (IV) thrombolysis carry the risk of intracerebral hemorrhage. PURPOSE: This study aimed to delve deeper into the risk of intracerebral hemorrhage and its subtypes associated with mechanical thrombectomy with or without IV thrombolysis to contribute to better decision-making in the treatment of acute ischemic stroke due to large-vessel occlusion. DATA SOURCES: PubMed, EMBASE, and Scopus databases were searched for relevant studies from inception to September 6, 2023. STUDY SELECTION: The eligibility criteria included randomized clinical trials or post hoc analysis of randomized controlled trials that focused on patients with acute ischemic stroke in the anterior circulation. After screening 4870 retrieved records, we included 9 studies (6 randomized controlled trials and 3 post hoc analyses of randomized controlled trials) with 3241 patients. DATA ANALYSIS: The interventions compared were mechanical thrombectomy + IV thrombolysis versus mechanical thrombectomy alone, with the outcome of interest being any form of intracerebral hemorrhage and symptomatic intracerebral hemorrhage after intervention. A common definition for symptomatic intracerebral hemorrhage was pooled from various classification systems, and subgroup analyses were performed on the basis of different definitions and anatomic descriptions of hemorrhage. The quality of the studies was assessed using the revised version of Cochrane Risk of Bias 2 assessment tool. Meta-analysis was performed using the random effects model. DATA SYNTHESIS: Eight studies had some concerns, and 1 study was considered high risk. Overall, the risk of symptomatic intracerebral hemorrhage was comparable between mechanical thrombectomy + IV thrombolysis and mechanial thrombectomy alone (risk ratio, 1.24 [95% CI, 0.89–1.72]; P = .20), with no heterogeneity across studies. Subgroup analysis of symptomatic intracerebral hemorrhage showed a non-significant difference between 2 groups based on the National Institute of Neurological Disorders and Stroke (P = .3), the Heidelberg Bleeding Classification (P = .5), the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (P = .4), and the European Cooperative Acute Stroke Study III (P = .7) criteria. Subgroup analysis of different anatomic descriptions of intracerebral hemorrhage showed no difference between the 2 groups. Also, we found no difference in the risk of any intracerebral hemorrhage between two groups (risk ratio, 1.10 [95% CI, 1.00–1.21]; P = .052) with no heterogeneity across studies. LIMITATIONS: There was a potential for performance bias in most studies. CONCLUSIONS: In this systematic review and meta-analysis, the risk of any intracerebral hemorrhage and symptomatic intracerebral hemorrhage, including its various classifications and anatomic descriptions, was comparable between mechanical thrombectomy + IV thrombolysis and mechanical thrombectomy alone.